Latest news
26.04.2012 25.04.2012 Изменилась контактная информация компании!
Articles
Снижение продолжительности и качества жизни у больных, перенесших боль-шие ампутации нижних конечностей, заставляет хирургов использовать любые воз-можности для выполнения реваскуляризирующей операции. На протяжении последних 13 лет для протезирования/шунтирования периферических артерий мы применяем эпоксиобработанные биопротезы («КемАнгиопротезы») диаметром 4-7мм, длиной от 23 до 64см и толщиной стенки 1-1,2мм.

Vascular Graft Bioprosthesis KemAngioprotez

KemAngioprotez is the world,s only blood vessel prosthesis made from animal tissue. It is used
for replacement of blood stream segments. It has been in surgical use since 1993.

Native architectonics retained

A KemAngioprotez represents part of a bovine inner thoracic artery, treated with epoxy
compounds. To obtain the required length vascular xenoprostheses are made of one, two or
three native vascular segments. The segments are joined by anastamosis with an unbroken
blanket suture.

Implantation properties

• Vascular substitutes retain their initial elastic and biomechanical characteristics: their
strength and elastoplasticity do not differ from those of native arteries, which is due to
diepoxy treatment.
• Much better patency as compared to that of alloprostheses.
• The prostheses are extensible and expansible, they maintain their shape, have smooth
luminal surface and suture easily.
• The prostheses show optimal correlation of diameters, wall thickness and anastomose easily
to patient’s arteries. The walls do not cut through or fragment at suturing.
• No aneurismal deformation or ruptures as well as contamination.
• The clinical results for KemAngioprotez bear out the experimental data on the effects of
diepoxy treatment on the reduction of calcification and structure degeneration risks.

Particular qualities of morphological adaptation to recipient arteries

• The prostheses boast high biological compatibility of epoxy-treated xenomaterials with
recipient tissues.
• They retain convergency of native arteries and do not “fold” at anastomosing. Being loaded
functionally they bend evenly generating no hemodynamic gradients, which is important for a
knee-joint location.
• Additional heparin modification reduces clot formation in anastomosis zone.

* Nominal bioprosthesis length. The length of the bioprosthesis can be greater than the nominal.

Ordering information:
KemAngioprotez launched on the russian market in 1996.
The dates of the outside-Russia market launch are expected in early 2012 after obtaining CE mark.